| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Moracin M targets phosphodiesterase-4 (PDE4), an enzyme that hydrolyzes cyclic AMP (cAMP) and plays critical roles in inflammatory and immune responses. It is a potent PDE4 inhibitor with selectivity for PDE4D2 (IC50 = 2.9 μM) and PDE4B2 (IC50 = 4.5 μM) over PDE5A1 (IC50 > 40 μM) and PDE9A2 (IC50 > 100 μM). By inhibiting PDE4, Moracin M increases cAMP levels, leading to anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro, Moracin M is a potent PDE4 inhibitor with IC50 values of 2.9 μM for PDE4D2, 4.5 μM for PDE4B2, >40 μM for PDE5A1, and >100 μM for PDE9A2. These in vitro properties make Moracin M a valuable tool for studying PDE4 function and its role in inflammation and immune responses. It is a phenolic component isolated from Mori Cortex.
|
| ln Vivo |
In vivo activity of Moracin M has not been extensively reported. As a PDE4 inhibitor with anti-inflammatory potential, it may have applications in treating inflammatory diseases. However, detailed in vivo efficacy data are limited in publicly available sources. Moracin M is primarily used as a research tool for studying PDE4 biology.
|
| Enzyme Assay |
The in vitro enzyme assay for Moracin M involves measuring its inhibition of PDE4 enzymatic activity. Recombinant PDE4 isoforms (PDE4D2, PDE4B2, PDE5A1, PDE9A2) are incubated with the compound at various concentrations in the presence of a cAMP or cGMP substrate. Enzyme activity is measured by quantifying the production of AMP or GMP using radiometric, luminescent, or fluorescence-based assays. The IC50 for PDE4 inhibition is calculated from dose-response curves.
|
| Cell Assay |
The in vitro cell-based assay for Moracin M involves culturing immune cells (e.g., macrophages, lymphocytes) and treating them with the compound to assess effects on inflammatory responses. Cells are treated with Moracin M at various concentrations, and cAMP levels are measured using ELISA. Inflammatory cytokine production (e.g., TNF-α, IL-6) is measured by ELISA. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for Moracin M have not been extensively reported. If conducted, such studies might involve mouse models of inflammatory diseases, where Moracin M is administered orally or intraperitoneally and inflammatory markers are assessed. Standard protocols for inflammation models would be employed. No specific data are available.
|
| ADME/Pharmacokinetics |
Moracin M has a molecular weight of 242.23 and a molecular formula of C14H10O4. It is a polyphenol and phytoalexin with PDE4 inhibitory activity. The compound's pharmacokinetic properties, including oral bioavailability and half-life, have not been extensively characterized. It can be formulated for in vivo administration. Detailed PK parameters are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Moracin M has not been systematically evaluated. As a natural product with PDE4 inhibitory activity, it may have a favorable safety profile, but this has not been confirmed in controlled toxicology studies. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References |
|
| Additional Infomation |
Moraxine M belongs to the benzofuran class of compounds. It has been reported to exist in mulberry trees (Morus lhou), cathayana mulberry trees, and other organisms with relevant data.
Moracin M is a naturally occurring polyphenol and research compound, not approved for clinical use. It is found in Morus australis and Mori Cortex and is a potent PDE4 inhibitor with IC50 values of 2.9 μM (PDE4D2) and 4.5 μM (PDE4B2). Moracin M is a valuable tool for studying PDE4 function and its role in inflammation and immune responses. |
| Molecular Formula |
C14H10O4
|
|---|---|
| Molecular Weight |
242.23
|
| Exact Mass |
242.057
|
| Elemental Analysis |
C, 69.42; H, 4.16; O, 26.42
|
| CAS # |
56317-21-6
|
| PubChem CID |
185848
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
369.3±22.0 °C at 760 mmHg
|
| Melting Point |
271-273 ºC
|
| Flash Point |
177.1±22.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.730
|
| LogP |
2.37
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LHPRYOJTASOZGJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H10O4/c15-10-2-1-8-5-13(18-14(8)7-10)9-3-11(16)6-12(17)4-9/h1-7,15-17H
|
| Chemical Name |
5-(6-Hydroxy-1-benzofuran-2-yl)benzene-1,3-diol
|
| Synonyms |
Moracin M;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~68.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1283 mL | 20.6415 mL | 41.2831 mL | |
| 5 mM | 0.8257 mL | 4.1283 mL | 8.2566 mL | |
| 10 mM | 0.4128 mL | 2.0642 mL | 4.1283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
